skip to main content
OSTI.GOV title logo U.S. Department of Energy
Office of Scientific and Technical Information

Title: Can brain thallium 201 SPECT substitute for F-18-FDG PET in detecting recurrent brain tumor in the presence of radiation necrosis; correlation with biopsy/surgery results

Journal Article · · Journal of Nuclear Medicine
OSTI ID:198081
; ;  [1]
  1. Univ. of New York, Stony Brook, NY (United States); and others

F-18-FDG PET man has been largely successful in differentiating between radiation necrosis and recurrent brain tumors. Because of the expense and unavailability of PET scanners in most clinical centers, Tl-201 SPECT scan may offer an alternative. Therefore, we have evaluated both techniques in 18 patients (13 men and 5 women) whose ages range from 28 to 74 year old. Eleven patients had glioblastoma multiformi and 4 patients high grade astrocytoma and 3 patient meningiosarcoma. All patients received radiation therapy (5500-6000 Rad) and 13 patients received also chemotherapy. PET scan was performed 40-60 min. after 5-10 mCi of F-18 FDG (i.v.) and SPECT 30 min. after 4.6 mCi of Tl-201 chloride (i.v.). Severe FDG hypometabolism was evident in the irradiated regions, in all patients. Evidence of tumor recurrence was seen in 15 patients by both FDG PET and Thallium 201 SPECT. The ratio of peak pixel uptake of suspected tumor to that of normal cortex for FDG ranged from 0.67 to 1.5 with a mean of 1.02. The ratio of peak pixel uptake of thallium 201 in the suspected lesion to that of the contralateral scalp area ranges from 0.8 to 1.9 with mean of 1.1. There was concordance between the findings of PET and SPECT in 16/18 patients. However, the volume of involvement differs in these patients; most likely secondary to different mechanisms of uptake and both studies may complement each other. Subsequent biopsy/surgery in 11 patients confirmed tumor recurrence in 10 out of 11 patients. The findings suggest that thallium 201 brain SPECT scan can provide similar (but not identical) information regarding brain tumor recurrence in these patients.

OSTI ID:
198081
Report Number(s):
CONF-940605-; ISSN 0161-5505; TRN: 95:007029-0233
Journal Information:
Journal of Nuclear Medicine, Vol. 35, Issue Suppl.5; Conference: 41. annual meeting of the Society of Nuclear Medicine, Orlando, FL (United States), 5-8 Jun 1994; Other Information: PBD: May 1994
Country of Publication:
United States
Language:
English